English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

© 2011 The Authors. doi: 10.2340/00015555-1097 Journal Compilation © 2011 Acta Dermato-Venereologica. ISSN 0001-5555 The mammalian target of rapamycin (mTOR) is a key regulatory protein in cancer. In particular, mTOR is involved in the control of cellular proliferation, survival (inhibition of apoptosis) and angiogenesis (1). This is the basis for the development of new drugs to inhibit this target in oncology. mTOR inhibitors act by selectively inhibiting the PI3K/AKT/mTOR intracellular signalling pathway in the tumour cell. The US Food and Drug Administration and the European Medicines Agency have recently approved temsirolimus (Torisel®, intravenous administration, 25 mg weekly) and everolimus (Afinitor®, oral administration, 10 mg daily) for use in metastatic renal cell carcinoma. These drugs have good safety profiles, but are not free of adverse effects. Notably, during the development phases of everolimus and temsirolimus, dermatological toxicity emerged as the most frequent form of toxicity, affecting up to 70% of patients (2–5). For example, ungual toxicity was observed in 5–46% of patients, but no clinical description was provided in these studies (2–4). We report here for the first time periungual toxicity associated with the use of anticancer mTOR inhibitors.

Paronychia and Pyogenic Granuloma Induced by New Anticancer mTOR Inhibitors